Bellevue Life Sciences Ac... (BLAC)
NASDAQ: BLAC
· Real-Time Price · USD
3.01
-3.72 (-55.27%)
At close: Feb 14, 2025, 3:53 PM
Bellevue Life Sciences Acquisition Balance Sheet Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q4 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Dec 31, 2021 |
Cash & Equivalents | 1.58M | 1.6M | 66.14K | 12.24K | 119.12K | 3.64K | 15.42K | 57.95K | 1.18K | 348.8K | 124.5K | 68.83K | 74.17K | 4.76K |
Short-Term Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Long-Term Investments | n/a | n/a | 1.85M | 20.89M | 20.47M | 37.21M | 36.61M | 72.05M | 71.44M | 70.63M | n/a | n/a | n/a | n/a |
Other Long-Term Assets | 394.08K | 350.96K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1.1M | 1.09M | 984.99K | 700.33K |
Receivables | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Inventory | 198.83K | 736.63K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Current Assets | 1.09M | 1.13M | 389.26K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Total Current Assets | 2.88M | 3.47M | 455.4K | 39.61K | 166.83K | 68.18K | 22.63K | 82.41K | 58.98K | 429.88K | 124.5K | 68.83K | 74.17K | 4.76K |
Property-Plant & Equipment | 62.79K | 68.59K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Goodwill & Intangibles | 181.98M | 170.57M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Total Long-Term Assets | 182.54M | 171.08M | 1.85M | 20.89M | 20.47M | 37.21M | 36.61M | 72.05M | 71.44M | 70.63M | 1.1M | 1.09M | 984.99K | 700.33K |
Total Assets | 185.42M | 174.55M | 2.3M | 20.93M | 20.63M | 37.27M | 36.63M | 72.14M | 71.49M | 71.06M | 1.23M | 1.16M | 1.06M | 705.09K |
Account Payables | n/a | n/a | n/a | 1.26M | 1.05M | 1.55M | n/a | n/a | 266.49K | 386.43K | 34K | 20.7K | 800.00 | 2.85K |
Deferred Revenue | n/a | n/a | n/a | n/a | n/a | -933.05K | n/a | -112.58K | n/a | n/a | n/a | n/a | n/a | -2.85K |
Short-Term Debt | 42.28K | 287.51K | 1.76M | 1.78M | 1.5M | 135K | n/a | 200K | n/a | n/a | 1.2M | 900K | 900K | 400K |
Other Current Liabilities | 15.81M | 13.6M | 4.96M | n/a | 1.68M | 2M | 1.51M | 517.35K | 283.49K | n/a | n/a | n/a | n/a | n/a |
Total Current Liabilities | 15.86M | 13.88M | 6.72M | 3.94M | 3.42M | 2.75M | 2.04M | 1.11M | 541.37K | 403.43K | 1.26M | 1.19M | 1.06M | 707.21K |
Long-Term Debt | 20.41K | 279.37K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Long-Term Liabilities | 1.8K | 1.66K | 2.07M | 2.07M | 2.07M | 2.07M | 2.07M | 2.07M | 2.07M | 2.07M | n/a | n/a | n/a | n/a |
Total Long-Term Liabilities | 30.41M | 28.38M | 2.07M | 2.07M | 2.07M | 2.07M | 2.07M | 2.07M | 2.07M | 2.07M | 1.23M | n/a | n/a | n/a |
Total Liabilities | 46.26M | 42.27M | 8.79M | 6.01M | 5.49M | 4.82M | 4.11M | 3.18M | 2.61M | 2.47M | 1.26M | 1.19M | 1.06M | 707.21K |
Total Debt | 62.68K | 566.88K | 1.76M | 1.78M | 1.5M | 135K | n/a | 200K | n/a | n/a | 1.2M | 900K | 900K | 400K |
Common Stock | 1.98K | 1.93K | 1.85M | 20.67M | 20.05M | 36.77M | 36.43M | 71.42M | 70.98M | 70.41M | 173.00 | 173.00 | 173.00 | 173.00 |
Retained Earnings | -30.18M | -30.57M | -8.33M | -5.75M | -4.9M | -4.31M | -3.91M | -2.46M | -2.09M | -1.83M | -62.51K | -48.26K | -28.23K | -27.12K |
Comprehensive Income | 6.98M | 241.69K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shareholders Equity | 139.15M | 132.28M | -6.49M | 14.91M | 15.15M | 32.46M | 32.52M | 68.96M | 68.88M | 68.58M | -37.51K | -23.26K | -3.23K | -2.12K |
Total Investments | n/a | n/a | n/a | 20.89M | 20.47M | 37.21M | 36.61M | 72.05M | 71.44M | 70.63M | n/a | n/a | n/a | n/a |